donald trump on glp 1 drug price deal: Burning questions after Lilly, Novo agreement What Trump's GLP-1 weight-loss drug

Sci Immunol (2021) 6(57):2

Medicare currently covers these medications for diabetes management but does not broadly cover them for obesity alone, which creates significant access gaps for patients who qualify clinically but not administratively

However, both constructs are independent and there is no reason why, for instance, an auristatin cannot be coupled with a pH-sensitive linker or a disulfide linker

These actions collectively contribute to glucose regulation and feelings of fullness, making GLP-1s and their synthetic mimics (GLP-1 Receptor Agonists or GLP-1RAs) powerful tools in managing metabolic health and weight